Acral lentiginous melanoma (ALM) is the less common subtype with singular characterization. TERT (human telomerase reverse transcriptase) promoter mutations have being described as recurrent in melanomas and infrequent in ALM, but their real incidence and clinical relevance is unclear. The objectives of this study were to describe the prevalence of TERT promoter mutations in ALM, and correlate with the molecular profile of other drive genes and clinical features. Sixty-one samples from 48 patients with ALM were analyzed. After DNA isolation, the mutation profiles of the hotspot region of BRAF, NRAS, KIT, PDGFRA, and TERT genes were determined by PCR amplification followed by direct Sanger sequencing. KIT, PDGFRA, and VEGFR2 gene amplification was performed by quantitative PCR. Clinical information such as survival, clinical stage, and Breslow tumor classification were obtained from medical records. TERT promoter mutations were found in 9.3% of the cases, BRAF in 10.3%, NRAS in 7.5%, KIT in 20.7%, and PDGFRA in 14.8% of ALM. None of the cases showed KIT, PDGFRA, or VEGFR2 gene amplification. We found an association between KIT mutations and advanced Clark level (IV and V, P = 0.043) and TERT promoter mutations with low mitotic index. No other significant associations were observed between mutation profile and patients' clinical features nor survival rates. Oncogenic TERT promoter mutations are present in a fraction of ALMs. No relevant associations were found between TERT mutation status and clinical/molecular features nor survival. Mutations of KIT and PDGFRA are the most common genetic alterations, and they can be therapeutic targets for these patients. Melanoma Res 26:93-99
Introduction
Cutaneous melanoma is the most aggressive skin cancer, with a rising incidence worldwide in the past few decades [1] . Different from the main melanoma subtypes, usually diagnosed in white populations with fair skin and hair, the acral lentiginous melanoma (ALM) is an infrequent counterpart, accounting for less than 2% of all melanoma cases [2, 3] . This subtype exhibits unique clinical characteristics, affecting only the palms of the hands, the soles of the feet, and the subungual area [4, 5] . In regions with vast contingent of non-white population, such as Asia, Africa, and part of America, ALM is a major concern, as it occurs in populations and skin areas that are not generally at risk for skin cancer, leading frequently to late diagnosis and low survival rates [6] [7] [8] . In Brazil, a country with high miscegenated and heterogeneous population with African, European and indigenous heritage, ALM is prevalent in some geographic areas [9] [10] [11] .
Over the past few years we have witnessed a fast growth in molecular characterization of melanomas, with great emphasis in alterations of cell signaling pathways [12, 13] . The mitogen-activated protein kinase pathway has a crucial role in melanoma development and progression [12, 14] . BRAF, an intracellular serine-threonine kinase, is mutated in ∼ 60% of cutaneous melanomas [12, 15, 16] . Ninety-five percent of such cases result in a V600E mutation, which involves a valine to glutamic acid substitution at position 600, which leads to a constitutive activation of the mitogen-activated protein kinase pathway [12, 14, 17] . Mutations are also frequent in another intracellular kinase, particularly in the NRAS gene, with a rate of 15-18% of mutated cases [12, 14, 17] . It has been reported that ALM exhibited a distinct molecular profile when compared with cutaneous melanoma [18] . In the ALM subtype, BRAF mutations are uncommon, and mutations were identified in upstream receptor tyrosine kinase, such as KIT (15-30%) and PDGFRA (6.8%) [12, 14, 17] . It was also reported that KIT and PDGFRA could be altered in ALM by gene amplification mechanisms of their 4p12 locus [18] [19] [20] . Besides these two oncogenes, this locus also harbors another important oncogene, KDR, also known as VEGFR2 (vascular endothelial growth factor receptor-2 gene) [21, 22] . Importantly, many of the mutated molecules in ALM have emerged for therapeutic targets, such as BRAF, KIT/ PDGFR, and VEGFR2 [23] [24] [25] .
Recently, another important cancer-related gene, telomerase reverse transcriptase (TERT), was described to be mutated in melanomas [26, 27] . TERT encodes a subunit of telomerase that, together with other components, elongates the telomere maintaining genomic integrity. Its upregulation has being demonstrated in several human cancers, and the promoter region of the gene is considered the most regulatory element for telomerase expression. TERT promoter mutations, namely at positions c. − 124 C > T and c. − 146 C > T, have being reported in up to 50% of cutaneous melanoma [26] . In ALM, the data are scarce, with few studies addressing its biological and clinical impacts [28] [29] [30] .
In the present study, we intend to determine the frequency of hotspot TERT promoter mutations in a series of ALM melanomas. Furthermore, we aimed to assess other major molecular features, such as BRAF, NRAS, KIT, PDGFRA mutations, as well as amplification of 4q12 locus (KIT/PDGFRA/VEGFR2), and correlate with TERT mutation status and with ALM clinicopathological features.
Materials and methods
Sixty-one formalin-fixed paraffin-embedded tissues from 48 ALM patients were retrieved from the files of the Department of Pathology at Barretos Cancer Hospital. All the patients were diagnosed between 1999 and 2013. Primary tumor samples were obtained from 48 cases. Eleven cases also presented lymph node (LN) samples and in two cases we assessed the distant metastasis. All cases were re-evaluated by a pathologist who confirmed the diagnosis and identified the tumor region for further molecular analysis. The study was conducted according to the national and institutional ethical policies, and it was previously approved by the Local Ethics Committee (CEP-548/2011).
DNA isolation from FFPE tissue
DNA was obtained from formalin-fixed paraffinembedded tissue sections representative of the tumor lesions, as previously described with some modifications [31] . Briefly, serially 10-μm-thick unstained sections of paraffin blocks were sectioned and one haematoxylin and eosin (H&E) section was used for identification and selection of the tumor area, which was macrodissected into a microfuge tube using a sterile needle (25 G -0.5 mm, Neolus, Terumo Corporation, Tokyo, Japan). The macrodissected tissue was deparaffinized by a serial wash with xylol and ethanol (100-70-50%) and allowed to air-dry. DNA was extracted using Qiagen's QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and quantified by NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). DNA samples were stored at − 20°C until further genetic analysis.
Mutation analysis of TERT, KIT, PDGFRA, and BRAF and NRAS hotspot regions
The analysis of hotspot mutations of TERT promoter regions (contained the sites of c. − 124:C > T and c. − 146:C > T), KIT (exons 9, 11, 13, and 17), PDGFRA [12, 14, 18] , BRAF (exon 15), and NRAS (codon12/13, 61), was performed by PCR followed by direct Sanger sequencing, as described previously [28, [31] [32] [33] . Briefly, using specific pairs of primers ( Supplementary Table 1 ), the target regions were amplified by PCR with an initial denaturation at 95°C for 15 min, followed by 40 cycles of 95°C denaturation for 45 s, specific annealing temperature for 90 s and 72°C elongation for 45 s, and 72°C final elongation for 7 min, in a Verity PCR machine (Applied Biosystems, Carlsbad, California, USA). Amplification of PCR products was confirmed by gel electrophoresis. Sequencing PCR was performed using a Big Dye terminator v3.1 cycle sequencing ready reaction kit (Applied Biosystems) and the ABI PRISM 3500 xL Genetic Analyzer (Applied Biosystems). All mutated cases were confirmed with a second PCR followed by sequencing.
Gene amplification analysis of KIT, PDGFRA, and VEGFR2 KIT, PDGFRA, and VEGFR2 gene amplification was performed by quantitative real-time PCR with LightCycler (Roche Molecular Biochemicals, Mannheim, Germany), using fluorescent hybridization probes and fluorescence resonance energy transfer for the detection of PCR amplification product, as previously described [34, 35] . In all assays, appropriate positive and negative controls of 4q12 loci amplification were included [36] . These controls had also been previously assessed by other methodologies, such as array-CGH and CISH [34, 36, 37] .
Statistical analysis
The SPSS 19.0 software (IBM Corp., Armonk, New York, USA) was used for all statistics analyses. To identify associations among clinicopathological characteristics and the molecular alterations, and to compare the prevalence of molecular findings with the previous reports, the Fisher exact test was used. Associations of the same variables with specific cancer survival were analyzed by the Kaplan-Meier method to estimate specific cancer survival, with log-rank testing used to evaluate differences between curves. The P-value established for the statistics significance was up to 0.05.
Results

Clinicopathological features
The characteristics of the patients are shown in Table 1 . The age ranged from 26 to 85 years old (mean 62 14.8), and men and women had similar distribution. One-third of the cases presented non-white skin phenotype. Primary lesions were thick and ulcerated in most cases and arose only on the hands in three (6.3%) cases. Localized disease represented half of the cases. Breslow tumor thickness ranged from 0.62 to 20.0 mm, with a median of 4.9 ( 4.6). Five-year-specific cancer survival rate for all patients was 51.5%. Follow-up ranged from 2 to 174 months, with a mean of 35.5 ( 30.4 ) and a median of 29.6. At the last evaluation, 20 patients (41.7%) were alive without disease, nine were alive with disease (18.8%), 17 were dead because of melanoma (35.4%), and two were dead because of other causes (4.1%).
Molecular profile
Because of the low amount and/or poor DNA quality yield in some samples, we were not able to obtain molecular profiles from all ALM cases. Table 2 summarizes the molecular results. In primary tumors, we observed the presence of 7.0% (3/43) TERT mutations, harboring the c. − 146 C > T mutation in all cases (Tables 2 and 3 ). We found a frequency of mutations of 20.7% for KIT, 14.8% for PDGFRA, 7.5% for NRAS, and 10.3% for BRAF genes (Table 2) . KIT, PDGFRA, and VEGFR2 copy numbers were normal in all analyzed cases. One case exhibited two mutations in PDGFRA: one at exon 12 and another on exon 14 (Table 3 ). In the comparison of primary and LN or skin metastasis, we observed a similar molecular status, except in one case that showed TERT mutated only in the LN metastasis ( Table 2) . One case exhibited the same BRAF mutation in both primary and LN metastases ( Table 2 ). The cooccurrence of mutations across specimens is demonstrated in Fig. 1 . Only BRAF mutations were exclusive. NRAS was mutated mutually only in one case with PDGFRA mutation, and the same was observed with TERT and KIT; KIT and PDGFRA presented comutated with two other mutations (Fig. 1 ).
Clinicopathological and molecular associations
We found a significant association between KIT mutation status and higher Clark levels (Table 4 ). We also observed an association between TERT mutations and lower mitosis index (Table 4 ). There were no significant TERT, telomerase reverse transcriptase; VEGFR2, vascular endothelial growth factor receptor-2. 
Discussion
In the present study, we described for the first time the molecular profile of Brazilian acrolentigenous melanomas. We showed that Brazilian patients exhibited a similar profile to the one described in the international literature [12,18-20,24,28-30,38-64] ( Table 5 ).
We found that TERT c. − 146C > T promoter mutation is present in 9.3% of patients, and this frequency was in concordance with the reported 7.6% (7/92) (P = 0.732) ( Table 5 ). However, our study represents the larger analysis of the gene hotspot region of TERT in this melanoma subtype ( Table 5 ). Previous studies in thyroid cancer and skin melanomas suggested an association of TERT mutation with other molecular alterations, such as BRAF [28] . In superficial melanomas, thyroid cancer, and gliomas, TERT promoter mutations have been also reported to be associated with older patients and worse patient prognosis [65] . In our study, we did not observe such molecular and clinical associations in acrolentigenous melanomas. The association with low mitotic index could be related to better prognosis, but the small number of mutated cases needs further confirmation in a larger series.
Acrolentigenous melanomas are known to harbor a distinct molecular profile of superficial melanomas. Compelling evidence showed the paramount role of KIT and PDGFRA alterations in the melanoma subtype [66] .
In the present study, we found a mutation frequency of 16.7 and 12.5% for KIT and PDGFRA, respectively. Among KIT mutations, 50% were located on exon 11 and the others were distributed among the other exons [9, 13, 17] , whereas 60% of PDGFRA mutations were located on exon 12 and the others were distributed on exons 14 and 18. These mutation rates are in accordance with previous descriptions of 13.1% (75/572) and 6.2% (9/145) (P = 0.145 and 0.108) ( Table 5 ). Some authors have identified KIT gene amplification as an alternative mechanism for KIT upregulation in these tumors [18] [19] [20] . However, we did not find any case with KIT gene amplification using quantitative real-time PCR, a very sensitive and specific methodology, previously optimized by us and reported by our group and other groups [34, 36, 67, 68] . We observed an association between KIT mutation and higher Clark staging, indicating that KIT could be associated with a more aggressive disease. The presence of KIT and PDGFRA alterations, namely mutations, has an important therapeutic impact. It has been shown that some melanoma patients exhibiting KIT/PDGFRA mutations, rather than gene amplification, can benefit from imatinib-based targeted therapy [69] . Recently, KIT/PDGFRA mutations have been found as targets for other small inhibitors, such as crenolanib and nilotinib [39, 70] . Therefore, we can anticipate that between 15 and 20% of Brazilian acrolentigenous melanoma patients would benefit from these above-mentioned therapeutic modalities. We also analyzed in this study the frequency of NRAS (codon12/13 and 61) and BRAF (exon 15) hotspot mutations. We found that NRAS was mutated in 6.3% of cases. This frequency was somehow below what is reported worldwide, which is above 11% (63/544) (P = 0.787) of cases (Table 5 ). However, NRAS frequency reports range from 0 to 47% (Table 5) ; therefore, there is not really a consensus in the literature, and this could be because of the distinct sizes of series analyzed in each study, or it could reflect the differences between populations.
With regard to BRAF, we observed the presence of 10.6% (all V600E) of mutated cases. This result is in line with the reported (16.4% -119/724) (P = 0.639) ( Table 5) , where the values range from 0 to 33% of BRAF mutated cases. BRAF mutations were exclusive events. Besides the low frequency of all mutations, they were mutually present at least in one-third of the cases, except for the BRAF, corroborating the high spectrum of melanoma mutations reported.
In conclusion, we have molecularly characterized a series of 48 ALMs. We have shown that less than 10% of patients harbor the recurrent TERT promoter mutation, and KIT represents the most mutated gene (21%), followed by PDGFRA (15%), in this series. These results could help in the selection of other alternative and potential therapeutic options for Brazilian acral lentiginous melanoma patients.
